Clinical Trial Update: CMP-001 for Relapsed and Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial CMP-001 for relapsed and refractory lymphoma (Phase 1/Phase 2) has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• CMP-001

Snippet

Sponsor: Umar Farooq | Conditions: Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-03-30